These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18760517)

  • 1. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis.
    Streja E; Kovesdy CP; Greenland S; Kopple JD; McAllister CJ; Nissenson AR; Kalantar-Zadeh K
    Am J Kidney Dis; 2008 Oct; 52(4):727-36. PubMed ID: 18760517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
    Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
    Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization of hemoglobin in patients with CKD may cause harm: but what is the mechanism?
    Littlewood TJ
    Am J Kidney Dis; 2008 Oct; 52(4):642-4. PubMed ID: 18805344
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.
    Bradbury BD; Danese MD; Gleeson M; Critchlow CW
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):630-7. PubMed ID: 19261826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
    Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
    Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.
    Ogawa C; Tsuchiya K; Tomosugi N; Kanda F; Maeda K; Maeda T
    PLoS One; 2017; 12(6):e0179608. PubMed ID: 28662118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
    Tarng DC; Huang TP; Chen TW
    Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
    Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
    Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
    Ahluwalia N; Skikne BS; Savin V; Chonko A
    Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery.
    Kaufner L; von Heymann C; Henkelmann A; Pace NL; Weibel S; Kranke P; Meerpohl JJ; Gill R
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012451. PubMed ID: 32790892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
    Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
    J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impacts of recombinant human erythropoietin treatment during predialysis periods on the progression of chronic kidney disease in a large-scale cohort study (Co-JET study).
    Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
    Ther Apher Dial; 2014 Apr; 18(2):140-8. PubMed ID: 24720404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients.
    Chiang WC; Tsai TJ; Chen YM; Lin SL; Hsieh BS
    Clin Nephrol; 2002 Nov; 58(5):363-9. PubMed ID: 12425487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.
    Fishbane S; Berns JS
    Kidney Int; 2005 Sep; 68(3):1337-43. PubMed ID: 16105069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.
    Cazzola M; Messinger D; Battistel V; Bron D; Cimino R; Enller-Ziegler L; Essers U; Greil R; Grossi A; Jäger G; LeMevel A; Najman A; Silingardi V; Spriano M; van Hoof A; Ehmer B
    Blood; 1995 Dec; 86(12):4446-53. PubMed ID: 8541533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients.
    Roberts TL; Obrador GT; St Peter WL; Pereira BJ; Collins AJ
    Kidney Int; 2004 Dec; 66(6):2429-36. PubMed ID: 15569336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
    Servilla KS; Singh AK; Hunt WC; Harford AM; Miskulin D; Meyer KB; Bedrick EJ; Rohrscheib MR; Tzamaloukas AH; Johnson HK; Zager PG
    Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.